Common Stock
- Symbol
- PMI
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Picard Medical, Inc.
PMINYSE_AMERICANEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 19, 2026, Picard Medical, Inc. (the "Company") published an investor presentation (the "Presentation") that it plans to use for investor relations and other purposes. A copy of the presentation is attached as Exhibit 99.1 and is incorporated herein by reference.…
Company context
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona - based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 23, 2026
- S-3 filingOct 22, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 13, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesOct 6, 2026
- 10-Q filingAug 19, 2026
Registered securities in this filing
Picard Medical, Inc. · 8-K · Filed 2026-08-20
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On August 19, 2026, Picard Medical, Inc. (the "Company") published an investor presentation (the "Presentation") that it plans to use for investor relations and other purposes. A copy of the presentation is attached as Exhibit 99.1 and is incorporated herein by reference.
The information in this report and the exhibit attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────────────────────
99.1 Investor Presentation (August 19, 2026)
104 Cover Page Interactive Data File (formatted as Inline XBRL document).